|
|
|
| Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China |
| Xin Jin a , b , Bin Fu a , Zheng-Jie Wu a , Xiao-Qin Zheng a , Jian-Hua Hu a , Lin-Feng Jin a , Ling-Ling Tang a , b , c , ∗ |
a State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
b College of Medicine, Shaoxing University, Shaoxing 312000, China
c Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University, Shulan International Medical College, Hangzhou 310022, China
∗ Corresponding author at: Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou 310 0 03, China.
E-mail address: 1196040@zju.edu.cn (L.-L. Tang). |
|
|
|
Abstract Background: Serum chitinase-3-like protein 1 (CHI3L1) is a potential biomarker for fibrosis assessment. We aimed to evaluate serum CHI3L1 as a noninvasive diagnostic marker for chronic hepatitis B virus-related fibrosis.
Methods: Serum CHI3L1 levels were measured by ELISA in 134 chronic hepatitis B (CHB) patients. Sig- nificant fibrosis was defined as a liver stiffness > 9.7 kPa. The performance of CHI3L1 was assessed and compared to that of other noninvasive tests by receiver operating characteristic (ROC) analysis.
Results: Serum CHI3L1 levels were significantly higher in CHB patients with significant hepatic fibrosis ( ≥F2) than in those without significant hepatic fibrosis ( < F2) (56.5 ng/mL vs. 81.9 ng/mL, P < 0.001). In CHB patients, the specificity and sensitivity of CHI3L1 for predicting significant fibrosis were 75.6% and 59.1%, respectively, with a cut-off of 76.0 ng/mL and an area under the ROC curve of 0.728 (95% CI: 0.637–0.820).
Conclusions: Serum CHI3L1 levels could be an effective new serological biomarker for the diagnosis of liver fibrosis. Moreover, CHI3L1 is feasible in monitoring disease progression.
|
|
|
|
|
|
|
|
|
2020, Vol. 19 
